Press Releases

Myriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight^® Test to Improve Mental Health Outcomes for Veterans

November 10, 2017Shari Basch

2,000 Patient Study Will Leverage GeneSight Test to Guide Therapy Selection SALT LAKE CITY, Nov. 10, 2017 – Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ: MYGN), today…

Myriad Announces GeneSight® Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder

November 2, 2017bsmith

GeneSight Demonstrated Statistically Significant Improvement in the Gold Standard Clinical Outcomes of Remission and Response SALT LAKE CITY, Nov. 02, 2017 (GLOBE NEWSWIRE) — Assurex Health, a wholly-owned subsidiary of…

GeneSight^® Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodiazepine Use

October 19, 2017Shari Basch

Positive Results Presented at the 25th World Congress of Psychiatric Genetics Salt Lake City, Oct. 19, 2017 – Assurex Health, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced…

Myriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight® Test to Improve Mental Health Outcomes for Veterans

Myriad Announces GeneSight® Psychotropic Results from a Large Prospective Trial in Patients with Major Depressive Disorder

GeneSight® Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodiazepine Use

Myriad Collaborates with Department of Veterans Affairs in Large Trial Evaluating the GeneSight^® Test to Improve Mental Health Outcomes for Veterans

GeneSight^® Shown to Statistically Significantly Improve Generalized Anxiety Disorder Treatment Response and Decrease Benzodiazepine Use